Alpha Cognition (ACOG) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual general meeting scheduled for June 19, 2025, to address key governance and compensation matters.
Shareholders will consider financial statements, elect directors, appoint auditors, and vote on a new stock and incentive plan.
Proxy materials are available online, and shareholders are encouraged to vote by proxy if unable to attend.
Voting matters and shareholder proposals
Proposals include setting the board at six directors, electing directors, appointing Manning Elliott LLP as auditor, and approving the 2025 Stock and Incentive Plan.
Shareholders may submit proposals for the next annual meeting by January 5, 2026, for proxy inclusion.
Voting rights: one vote per common or preferred share; no cumulative voting.
Board of directors and corporate governance
Board consists of six members, majority deemed independent under Nasdaq rules.
Committees: Audit (Len Mertz, John Havens, Rob Bakshi), Compensation (Phillip Mertz, Rob Bakshi), Governance and Nomination (Len Mertz, Robert Wills, John Havens).
Board and committees met regularly in 2024; all directors attended at least 75% of meetings.
Board diversity, director qualifications, and annual performance assessments are emphasized.
Code of Business Conduct and Ethics and anti-hedging/insider trading policies in place.
Latest events from Alpha Cognition
- FDA-approved ZUNVEYL launches in March, targeting LTC Alzheimer's with improved tolerability.ACOG
Investor Update9 Jan 2026 - ZUNVEYL launched in US, $52.8M raised, and strong liquidity supports global expansion.ACOG
Q4 202427 Dec 2025 - Biopharma seeks up to $250M to fund Alzheimer's drug launch and pipeline, with $75M ATM offering.ACOG
Registration Filing16 Dec 2025 - 2.38M shares registered for resale; ZUNVEYL launch and Asia-Pacific deal drive growth.ACOG
Registration Filing16 Dec 2025 - ZUNVEYL's launch and Asia-Pacific licensing drive growth amid ongoing net losses and Nasdaq listing.ACOG
Registration Filing16 Dec 2025 - ZUNVEYL targets major growth in 2026 with new data, expanded access, and global milestones.ACOG
Fireside Chat3 Dec 2025 - Shareholders can request financial statements by mail or online for greater transparency.ACOG
Proxy Filing2 Dec 2025 - AGM to vote on directors, auditors, and 2025 stock plan; board recommends approval.ACOG
Proxy Filing2 Dec 2025 - IPO funds will support the U.S. launch of an Alzheimer's drug, but financial risks remain high.ACOG
Registration Filing29 Nov 2025